Corbus Pharmaceuticals completes enrollment in obesity drug trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
April 14, 2026 8:01 AM EDTOn track to complete 16-week, dose-finding Phase 1b study (n=240) in summer 2026
Phase 1b data will build upon Phase 1a findings that demonstrated weight loss of nearly 3% at 14 days in individuals with obesity
CRB-913 is a non-incretin daily oral small molecule with the potential to deliver a therapeutic option for weight loss and long-term weight management
NORWOOD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new... More
